Vaxart Inc
NASDAQ:VXRT
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.5252
1.41
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VXRT stock under the Base Case scenario is 0.6969 USD. Compared to the current market price of 0.7222 USD, Vaxart Inc is Overvalued by 4%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Vaxart Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for VXRT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Vaxart Inc
Balance Sheet Decomposition
Vaxart Inc
Current Assets | 71.5m |
Cash & Short-Term Investments | 62.6m |
Receivables | 4.8m |
Other Current Assets | 4.2m |
Non-Current Assets | 42.2m |
PP&E | 32.9m |
Intangibles | 8.4m |
Other Non-Current Assets | 851k |
Current Liabilities | 15.8m |
Accounts Payable | 3.6m |
Accrued Liabilities | 8.7m |
Other Current Liabilities | 3.5m |
Non-Current Liabilities | 18m |
Long-Term Debt | 1.6m |
Other Non-Current Liabilities | 16.4m |
Earnings Waterfall
Vaxart Inc
Revenue
|
13.9m
USD
|
Operating Expenses
|
-89m
USD
|
Operating Income
|
-75m
USD
|
Other Expenses
|
-612k
USD
|
Net Income
|
-75.7m
USD
|
Free Cash Flow Analysis
Vaxart Inc
USD | |
Free Cash Flow | USD |
Vaxart's Q2 2024 revenue rose to $6.4 million, up from $1.4 million in Q2 2023, primarily due to a BARDA contract. They received a $64.7 million payment post-quarter-end, supporting the upcoming COVID-19 Phase IIb trial, anticipated to start in the latter half of 2024, pending FDA alignment. Norovirus program discussions with the FDA are ongoing, with positive recent trial results. Vaxart ended the quarter with $62.6 million in cash and equivalents and expects a cash runway into 2026.
What is Earnings Call?
VXRT Profitability Score
Profitability Due Diligence
Vaxart Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Vaxart Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
VXRT Solvency Score
Solvency Due Diligence
Vaxart Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Vaxart Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VXRT Price Targets Summary
Vaxart Inc
According to Wall Street analysts, the average 1-year price target for VXRT is 4.93 USD with a low forecast of 2.525 USD and a high forecast of 8.4 USD.
Dividends
Current shareholder yield for VXRT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
VXRT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.
Contact
IPO
Employees
Officers
The intrinsic value of one VXRT stock under the Base Case scenario is 0.6969 USD.
Compared to the current market price of 0.7222 USD, Vaxart Inc is Overvalued by 4%.